Prognostic value of STC1 in solid tumors: a meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Research

Background:

• Stanniocalcin-1 (STC1) is a hormone with potential roles in various cancers.
• Previous studies on STC1's prognostic value in solid tumors have yielded conflicting results.

Purpose of the Study:

• To systematically evaluate the prognostic significance of STC1 expression in patients with solid tumors.
• To resolve controversies regarding STC1 as a predictive biomarker for cancer outcomes.

Main Methods:

• A comprehensive literature search was conducted across PubMed, EMBASE, and Web of Science databases up to February 27, 2021.
• A meta-analysis was performed on 16 eligible studies, including 2942 participants.
• Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess associations.

Main Results:

• High STC1 expression was significantly associated with worse overall survival (HR: 1.91; 95% CI: 1.63-2.24).
• Elevated STC1 levels correlated with reduced disease-free survival, progression-free survival, or relapse-free survival (HR: 2.01; 95% CI: 1.34-3.02).

Conclusions:

• STC1 demonstrates significant potential as a prognostic biomarker in solid tumors.
• High STC1 expression is indicative of unfavorable survival outcomes for cancer patients.